Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco

Fig. 4

Incremental costs and QALYs of expanded PrEP coverage with and without earlier ART (Fig. 1b), with the origin corresponding to the status quo of low PrEP coverage and baseline ART guidelines. The solid lines show the incremental cost-effectiveness ratio (ICER) relative to the next best strategy. The dashed lines show the ICER relative to the next best strategy when earlier ART is not implemented. These strategies are dominated by similar strategies with earlier ART, meaning that they are not an efficient use of resources. Incremental costs and QALYs are calculated over a 20-year time horizon (2018–2038) and are discounted to the present at 3% annually. PrEP pre-exposure prophylaxis, ART antiretroviral therapy, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year

Back to article page